INOVIO PHARMACEUTICALS Forum: Community User: gerry

Ob die jemals einen DNA Impfstoff auf den Markt bringen 🤔

INOVIO Provides an Update on Lassa Fever and MERS Programs November 17, 2022 Download PDF Format (opens in new window) PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700), following initial analyses of data from studies conducted by INOVIO and funded by CEPI. Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer, said, "For the past four years, we have been pleased to collaborate with CEPI on its mission of accelerating the development of vaccines against epidemic and pandemic threats so that they can be accessible to all people in need. Although INO-4500 and INO-4700 were well-tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development. We continue to believe in the potential of our DNA medicine candidates based on their characteristics, including the ability to elicit durable T-cell responses, which could be important in the prevention and treatment of infectious diseases. INOVIO welcomes the opportunity to collaborate with CEPI in the future." The INO-4500 Lassa Fever trial was a Phase 1b study involving 220 participants in Ghana. With this trial, INO-4500 was the first product candidate to enter human clinical trials in West Africa targeting Lassa Fever. The INO-4700 trial was a Phase 2 study targeting the prevention of MERS. The first cohort of the trial involved 192 participants in Jordan, Kenya, and Lebanon. INOVIO intends to publish data to aid subsequent research.

Der Markt korrigiert und INO macht wie immer das, womit man nicht rechnet 🤔 Zumindest scheint es sich ja stabilisiert zu haben

Die Kostensenkungsmaßnamen haben schon erahnen lassen das da was im Busch war.

Advaccine und WHO prüfen weiter. Und bei INOVIO fallen so keine Kosten mehr an. Somit ist mehr Geld für den Rest der Pipeline übrig. Und dieser Rest ist recht vielversprechend.

War doch eh rausgeschmissenes Geld zuletzt. Wer lässt sich noch impfen?😅

Entwicklung von INO 4800 wird aufgegeben

https://twitter.com/InovioPharma/status/1585731603556352009?t=j9nJkP2QXleuCJRJgJEobg&s=19

🚀🌝 kommt später 😉

In diesem Marktumfeld sind + 4 % doch ganz ordentlich 🤔

Haben die News nichts bewirkt?

https://ir.inovio.com/news-releases/news-releases-details/2022/INOVIO-Reports-Positive-Interim-Phase-12-Results-for-INO-3107-for-the-Treatment-of-Recurrent-Respiratory-Papillomatosis/default.aspx

INOVIO meldet positive Zwischenergebnisse der Phase 1/2 für INO-3107 zur Behandlung von rezidivierender respiratorischer Papillomatose

https://www.nature.com/articles/s41467-022-33309-6

Bye bye Inovio

Denke, das ist dem gesamten Marktumfeld geschuldet. Wenn keine positive Nachricht kommt, wird auch kurzfristig m.E. nicht viel passieren